Roivant Sciences Ltd. (ROIV) · Oct 21, 2026 · Other events
Above the bar — Primary endpoint met in both trials; all key secondary endpoints statistically significant
Roivant’s Phase 3 brepocitinib earnings-free clinical update delivered broad uveitis trial success, supporting a potential second LISRAYA indication.
Roivant is moving from a cash-rich development platform into its first commercial phase, with LISRAYA already approved for dermatomyositis and brepocitinib being expanded into additional immune-mediated diseases. The company had already told investors that NIU data were expected in the second half of 2026, so the timing was anticipated; the clinical strength was not.
The trial result clears the key clinical bar decisively. Brepocitinib met the primary endpoint in both identical Phase 3 studies and also produced statistically significant results on every key secondary endpoint. 〔0〕
| Measure at Week 48 | CLARITY-1 brepocitinib vs placebo | CLARITY-2 brepocitinib vs placebo |
|---|---|---|
| Hazard ratio for treatment failure | 0.27 vs placebo (95% CI 0.17–0.43) | 0.22 vs placebo (95% CI 0.14–0.34) |
| Cumulative treatment failure | 35.4% vs 78.7% | 32.4% vs 77.8% |
| Steroid-free quiescence in both eyes | 58.8% vs 19.8% | 64.4% vs 19.4% |
| Macular-edema resolution among affected eyes | 40.4% vs 2.1% | 42.6% vs 7.0% |
| ≥5-point visual-function improvement | 36.4% vs 13.7% | 40.4% vs 14.1% |
The breadth matters more than any single p-value. The drug showed disease control, steroid-sparing benefit, improvement in retinal leakage, macular-edema resolution and patient-reported visual function across two studies and several disease subgroups. Pooled steroid-free quiescence was 62% versus 20% for placebo, while median time to treatment failure exceeded 48 weeks versus roughly 12 weeks on placebo. 〔1〕
This advances brepocitinib from a single-product launch into a broader franchise opportunity. LISRAYA is now commercially available for dermatomyositis, and NIU could become the next indication for the same medicine rather than a separate pipeline bet. The filing’s comparison with existing therapies is company-framed, so the durable conclusion is not that superiority is proven, but that the data give Roivant a credible basis to pursue a differentiated systemic, steroid-free NIU label.
Safety does not offset the efficacy signal, but it also does not remove the remaining regulatory step. Only 3% of participants discontinued because of adverse events and no new safety signals were reported. 〔2〕 The next value-creating milestone is the planned supplemental New Drug Application in the first half of 2027, not immediate revenue from NIU.
Bottom line: This is a meaningful clinical upgrade to Roivant’s brepocitinib story: an anticipated readout, but materially better and broader than a routine positive result. It supports a potential second commercial indication while leaving approval and launch execution still ahead.
NIU sNDA filing, first half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!